Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Feb;37(1):37-43.
doi: 10.4143/crt.2005.37.1.37. Epub 2005 Feb 28.

A preliminary results of a randomized trial comparing monthly 5-flourouracil and cisplatin to weekly cisplatin alone combined with concurrent radiotherapy for locally advanced cervical cancer

Young Seok Kim  1 , Seong Soo Shin, Eun Kyung Choi, Jong Hoon Kim, Seung Do Ahn, Sang-wook Lee, Heon-Jin Park, Young-Tak Kim, Jung-Eun Mok, Joo-Hyun Nam
Affiliations

A preliminary results of a randomized trial comparing monthly 5-flourouracil and cisplatin to weekly cisplatin alone combined with concurrent radiotherapy for locally advanced cervical cancer

Young Seok Kim et al. Cancer Res Treat. 2005 Feb.

Abstract

Purpose: To determine the superior chemotherapeutic regimen between monthly 5-FU plus cisplatin (FP) and weekly cisplatin alone in concurrent chemoradiotherapy for locally advanced cervical cancer, the compliance of treatment, response, survival and toxicities were analyzed between the two arms.

Materials and methods: Between March 1998 and December 2001, 61 patients with locally advanced cervical cancer (stage IIB through IVA) and negative para-aortic lymph nodes were randomly assigned to either 'monthly FP' (arm I, n=34) or 'weekly cisplatin' (arm II, n=27) with concurrent radiotherapy. The patients of arm I received FP (5-FU 1,000 mg/m(2)/day + cisplatin 20 mg/m(2)/day, for 5 days, for 3 cycles at 4 week intervals) and those of arm II received cisplatin (30 mg/m(2)/day, for 6 cycles at 1 week intervals) with concurrent radiotherapy. The radiotherapy consisted of 41.4 approximately 50.4 Gy external beam irradiation in 23 approximately 28 fractions to the whole pelvis, with high dose rate brachytherapy delivering a dose of 30 approximately 35 Gy in 6 approximately 7 fractions to point A. During the brachytherapy, a parametrial boost was delivered. The median follow-up period for survivors was 44 months.

Results: The compliance of treatment in monthly FP weekly cisplatin arms were 62 and 81%, respectively. The complete response rates at 3 months were 96 and 88% in arms I and II, respectively. The 4-year overall survival and disease free survival rates were 64 and 54% in the arm I and 77 and 66% in the arm II, respectively. The incidence of hematologic toxicity more than grade 2 was 29% in the arm I and 15% in the arm II. Only one patient in arm I experienced grade 3 gastrointestinal toxicity. No severe genitourinary toxicity was observed.

Conclusion: No significant difference was observed in the compliance, responses, survival rates and acute toxicities between the two treatment arms. More patients and further follow up will be required.

Keywords: Cervical neoplasm; Concurrent chemoradiotherapy; Randomized trials.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Treatment schemes.
Fig. 2
Fig. 2
Overall survival rates by treatment group. *monthly 5-FU+cisplatin †weekly cisplatin.
Fig. 3
Fig. 3
Disease free survival rates by treatment group. *monthly 5-FU+cisplatin, †weekly cisplatin.
Fig. 4
Fig. 4
Distant metastasis free survival rates by treatment group. *monthly 5-FU+cisplatin, †weekly cisplatin.
See this image and copyright information in PMC

References

    1. Gonzalez DG, Ketting BW, Bunningen BV, Dijk JD. Carcinoma of the uterine cervix stage IB and IIA: result of postoperative irradiation in patients with microscopic infiltration in the parametrium and/or lymph node metastasis. Int J Radiat Oncol Biol Phys. 1989;16:389–395. - PubMed
    1. Coia L, Won M, Lanciano R, Marcial VA, Martz K, Hanks G. The patterns of care outcome study for cancer of the uterine cancer: Results of the second national practice survey. Cancer. 1990;66:2451–2456. - PubMed
    1. Jampolis S, Andras EJ, Fletcher GH. Analysis of sites and causes of failures of irradiation in invasive squamous cell carcinoma of the intact uterine cervix. Radiology. 1975;115:681–685. - PubMed
    1. Leibel S, Bauer M, Wasserman T, Marcial V, Rotman M, Hornback N, et al. Radiotherapy with or without misonidazole in patients with stage IIIB or IVA squamous cell carcinoma of the uterine cervix: preliminary report of a radiation therapy oncology group randomized trial. Int J Radiat Oncol Biol Phys. 1987;13:541–549. - PubMed
    1. Piver MS, Barlow JJ, Vongtama V, Blumenson L. Hydroxyurea: a radiation potentiator in carcinoma of the uterine cervix. A randomized double-blind study. Am J Obstet Gynecol. 1983;147:803–808. - PubMed

LinkOut - more resources